Immunotherapy in Lung Cancer Articles | Page 2

FDA Approves 4-Week Nivolumab Dosing Schedule
The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.
Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC
David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.
Optimizing Immunotherapy in Lung Cancer
Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.
Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC
George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.
FDA Approves Durvalumab for Locally Advanced NSCLC
The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.
Immunotherapy Poised to Move Forward Into Stage III NSCLC
A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.
The combination of nivolumab and ipilimumab improved progression-free survival compared with chemotherapy in treatment-naïve patients with high tumor mutation burden non–small cell lung cancer.
Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial
Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.
Finding the Best Spot for PD-1/PD-L1 Antibodies in Advanced Lung Cancer
Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.
Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).
Publication Bottom Border
Border Publication